INTRODUCTION
Lung transplantation is the only treatment available for many patients suffering from end-stage pulmonary disease. While technical refinements, improvements in perioperative care and advances in immunosuppression have led to acceptable shortterm survival rates, long-term outcomes after lung transplantation are markedly worse than for other solid organs with 5-year survival rates of only 50% (see ref. 1) . Advances in long-term survival of other solid or cellular allografts have come through experimental manipulation of physiologically relevant mouse models, but no such models have existed for lungs 2 .
The desire to study lung transplantation biology in the mouse led to the development of the heterotopic tracheal transplantation model, which was first described in 1993 (see ref. 3 ). Transplantation of a tracheal segment into a subcutaneous pocket of an allogeneic recipient mouse is associated with progressive fibrotic occlusion of the airway lumen, a histological feature resembling occlusion of small airways in human lungs undergoing chronic rejection. The technical simplicity of this model, the availability of multiple transgenic and knockout strains and an extensive number of reagents, such as monoclonal antibodies, have led to its widespread use 4 . In fact, the heterotopic tracheal transplant model has been the most widely employed model for studying immunological aspects of lung transplantation and evaluation of immunosuppressive strategies for more than a decade 5 .
The importance of employing vascularized rather than nonvascularized transplant models has been already demonstrated for other organ systems. Nonvascularized grafts of neonatal cardiac tissue placed into a pouch in the ear pinna of a recipient mouse, e.g., lack direct interaction with recipient blood and vascular endothelium of the graft. This model makes it difficult to draw conclusions about vascularized human cardiac grafts 6 . Similarly, the heterotopic tracheal model differs from human lung transplants in that it lacks vascularization and aeration. Another potentially important consideration is that the heterotopic tracheal transplantation model uses segments of large airway, whereas airway changes after human lung transplantation are observed in small airways. Furthermore, the rapidity of development of fibrotic occlusion of heterotopic tracheal allografts does not mimic observations in human lungs or vascularized lung grafts in large animals or rats 7 . We have also recently demonstrated that airway epithelial cells remain intact in acutely rejected mouse lung transplants despite extensive vascular necrosis, further documenting the nonphysiological nature of the heterotopic tracheal transplant model 8 .
One of the unique features of lung grafts is that they are constantly exposed to the external environment. To this end, it has been demonstrated that the fate of human lung allografts can be regulated through exposure to agents that are introduced through the airway 9, 10 . Moreover, there has been recent interest in the inhalational administration of immunosuppressants 11 . As the heterotopic tracheal transplant model is not aerated and therefore not exposed to the external environment, it does not allow for the design of studies to address these important issues in lung transplantation biology.
The basis for the development of the orthotopic mouse lung transplant model in our laboratory was the orthotopic single lung transplant model in the rat 12, 13 . In mice and rats, unlike humans, the left lung contains only one lobe and makes up only 25% of the total lung mass. This makes single left lung transplantation feasible in the murine model without the need for circulatory support. Since the initial development of this model, we have established technical modifications of the model and now describe key steps that make the procedure easier to perform 8, 14, 15 .
In addition to its obvious value for the study of transplant immunobiology, this model may also provide a powerful tool for dissecting pathogenetic contributions of pulmonary stromal cells to other disease processes. This is possible because after transplantation of a mutant, syngeneic single lung near complete replacement of donor-derived hematopoietic cells occurs, whereas the non-hematopoietic stromal cells remain of donor origin. One can thus create a 'chimeric organ' without host irradiation or lungspecific expression of a transgene. The contralateral native lung may serve as an internal control within the same animal without global alteration of the host's immune system.
Scientific uses of the model Transplantation. We have already demonstrated that the transplantation of allografts in nonimmunosuppressed mice recreates histopathological findings observed in acutely rejected human lungs, whereas syngeneic grafts remain free of inflammation 8 . Notably, alloimmune responses can be suppressed with perioperative blockade of costimulatory signals 8 . Various organs differ in their cellular requirements to initiate graft rejection, and we have recently reported that, unlike cardiac grafts, the acute rejection of lungs is not dependent on CD4 + T lymphocytes 15, 16 . Extending the duration of cold ischemic storage is associated with a greater influx of neutrophils into the graft 14 . Therefore, this model may represent a more physiological tool in mice to study ischemia-reperfusion injury after lung transplantation than the hilar clamping model, which has been used extensively to date 17 . The Achilles heel of clinical lung transplantation remains bronchiolitis obliterans, which is defined as fibrotic occlusion of the small airways. At present, heterotopic tracheal transplantation and graft-versus-host disease after bone marrow transplantation are models used to study airway changes that mimic human chronic rejection 5, 18 . However, we have recently shown marked differences in the fate of airway epithelial cells in nonimmunosuppressed recipients of vascularized lung transplants compared with nonvascularized heterotopic tracheal transplants 8 , suggesting that observations made in heterotopic tracheal transplants need to be interpreted in the context of significant ischemic damage to the transplanted nonvascularized tissue. The vascularized lung transplant model will allow for the design of novel studies that examine the role of inflammatory stimuli, such as respiratory viral infections or exposure to gastric acid on airway epithelial cells in allogeneic lung grafts. Future studies will need to determine whether vascularized lung transplants develop airway changes of chronic rejection after long-term immunosuppression.
Tumor biology. One critical target for tumor rejection by T cells is the tumor stroma 19 . Experimental manipulation of tumor angiogenesis has proven to be a fruitful and rapidly growing field of therapeutic oncology 20 . Experimental methods traditionally used to study tumor nonhematopoietic stromal cells have relied on the creation of bone-marrow chimeras by lethal irradiation and rescue with bone marrow of a mutant genotype. Although widely used, such methodology can create many confounding variables, including graft-versus-host disease and autoimmune disorders due to altered development of T cells in a thymus where stromal and dendritic cells are of different genotype 21 . Lethal irradiation may also lead to unpredictable alteration in the physiology of irradiated antigen-presenting cells and tumor vasculature 22, 23 . The ability to selectively vary the nonhematopoietic tumor stroma in one particular organ without lethal irradiation or alteration in any other tissue or organ systems may prove useful to the field of tumor angiogenesis as well as tumor immunology.
To investigate the utility of mouse lung transplantation specifically for studying the stromal component of tumors, we transplanted C57BL/6 MHC Class I-deficient donors into C57BL/6 wild-type syngeneic recipients (B6I--B6) and used MHC Class I expression as a method for tracking donor and recipient cells. Such a system allows for validation of our model without induction of an immune response to the transplanted lung as might occur with the use of other transgenic models carrying reporter genes, such as GFP or b-galactosidase. Within 4 weeks of transplantation, near-complete replacement of the hematopoietic cells occurs in the recipient left lung, whereas the nonhematopoietic cells remain of donor genotype ( Fig. 1 ). We have documented this level of replacement as long as 2 months post-transplantation (data not shown).
To validate the lung transplantation model for the study of tumor biology, we injected 2 Â 10 5 B16 melanoma cells intravenously into six unmanipulated B6 mice in parallel to six sexand age-matched B6 recipients of syngeneic B6 left lung isografts (Fig. 2a,b) . After 20 d, the native left lung of the mice without a transplant had an identical tumor burden compared with the transplanted B6 lung (Fig. 2c) . This suggests that the orthotopic lung transplant can support tumor growth in a similar manner to the native lung further validating this model for the study of tumor biology. Experimental design General principles of cuff technique for establishing microvascular anastomoses. Unlike larger vessels, which can be secured directly by suture, the microscopic bronchial and vascular anastomoses required for mouse lung transplantation are performed using the cuff technique. The basic principles of this technique involve pulling the donor vessel though a rigid circular cuff sized to be slightly larger than the vessel (Fig. 3a) . The vessel is then folded over the cuff to expose the endothelial surface (or epithelial surface in case of the bronchus) and secured to the cuff with a 10-0 nylon tie (Fig. 3b,c ). This donor vessel is then inserted into the recipient vessel and the final anastomosis is secured with another 10-0 nylon tie (Fig. 3d) . . Custom-made stabilization clamp used for stabilizing the vascular and bronchial cuffs during cuff placement (Fig. 4) . 
PROCEDURE Preparation of bronchial and vascular cuffs TIMING
10 min for preparation of three cuffs 1| Prepare the bronchial and pulmonary venous cuffs from a 20-gauge Teflon angiocatheter 1 mm in length, not counting the extension handle, using a no. 11 scalpel with the metal needle of the angiocatheter as a cutting surface (see Experimental design and Fig. 5 ). Prepare the pulmonary artery (PA) cuff from a 24-gauge Teflon angiocatheter 0.6 mm in length in a similar manner.
Donor operation TIMING 10-15 min
2| Anesthetize the donor mouse with an i.p. injection of ketamine (50 mg kg À1 ) and xylazine (10 mg kg À1 ).
3| Place the anesthetized mouse under the operating microscope at Â10 magnification in a supine position. After ensuring adequate anesthesia, cut down on trachea and place a tie of 6-0 silk suture around the trachea.
4| Insert a 1-inch 20-gauge angiocatheter into the trachea and connect to the ventilator (Fig. 6a ).
5| Make a midline abdominal incision and incise the diaphragm circumferentially. Place a Halsted-mosquito hemostat on the diaphragm to retract it caudally and a similar hemostat on the xyphoid process to retract the sternum cranially, allowing for complete dissection of the diaphragm from the chest wall without damage to the lungs (Fig. 6b) .
6| Extend the incision cephalad to a midline sternotomy and place Halsted-mosquito hemostats on either side of the sternum for retraction and hemostasis from the bone edges (Fig. 6c) .
7| Inject 0.1 ml of heparin directly into the right lobe of the liver or the inferior vena cava. m CRITICAL STEP Intrahepatic injection may result in less bleeding from the residual needle hole than an injection into the inferior vena cava.
8| Remove thymus and excise the left and right atrial appendage to vent any drainage from the lungs.
9| Inject 3 ml of cold 4 1C Perfadex solution directly into the right ventricle using a 27 gauge needle on a 3-ml syringe to flush all the blood from the lungs. It is important to maintain ventilation during flushing to ensure even distribution of preservation solution.
10|
Clamp trachea proximally and then divide trachea distally. Dissect trachea caudally and posteriorly.
11| Remove heart-lung block and place in a small sterile Petri dish lined with gauze moistened with cold Perfadex, which is placed into a larger Petri dish filled with ice (Fig. 6d) .
12| Place small gauze on the left lung for retraction to expose the left hilum (Fig. 6e) .
13| Carefully dissect the hilar structures from each other using angled forceps. Start by dissecting the pulmonary vein (PV) from the bronchus, located in the most caudal aspect of the hilum (Fig. 6f) . Next dissect the PA, located in the most cranial aspect of the hilum from the bronchus in a similar manner (Fig. 6g) . placement of the cuff. Suspend the PA cuff B3 mm above the PA using the stabilization clamp and insert the PA inside the cuff (Figs. 3a and 6h ). Fold the PA over the cuff exposing the endothelial surface (Fig. 3b,c) . Secure around the cuff with 10-0 nylon (two knots; Figs. 3b and 6i) . (Fig. 7a) .
17| Place in right lateral decubitus position and clean with sterilization solution. It has been our preference to use clear chlorhexidine and 70% ethanol for chest wall preparation to prevent discoloration of the fur and skin (Fig. 7b) .
18| Incise the skin with scissors and perform the left thoracotomy completely with electrocautery. m CRITICAL STEP Bovie electrocautery should be used for all portions of this dissection, as it is important to minimize blood loss from the chest wall during this step.
19|
Enter the chest between ribs 3 and 4 and place two chest retractors (Fig. 7c) .
20| Place a sterilized 1/4-inch steel binder clip on recipient left lung and retract lung anteriorly to expose posterior hilum (Fig. 7d) . Dissect hilum bluntly using a sterile Q-tip. ? TROUBLESHOOTING 21| Move clip posteriorly to expose the anterior hilum for the rest of the dissection.
22| Dissect the PA from the bronchus using curved dissection forceps as far into the hilum as possible without tearing the vessel (Fig. 7e) .
23| Dissect the bronchus from the PV in a similar manner (Fig. 7f ).
24| Place a one-throw slipknot of 10-0 silk at the base of the PA and PV (in that order) to occlude the blood flow to the left lung. Place an aneurysm microclip at the base of the bronchus to isolate the ventilation to left lung (Fig. 7g) .
25| Place 10-0 nylon around the bronchus, PA and PV and leave loose (for future securing of cuffs). 26| Incise the recipient PA, bronchus and PV close to the recipient left lung using microscissors and gently dilate the vascular and bronchial openings using curved or straight forceps to create a large enough opening for placement of the donor cuffs.
27| Now cut the bronchus of the donor left lung flush with the donor trachea in order to create a long bronchial stump for placement of the cuff. Cuff the donor bronchus in a similar manner to the PA and PV. Secure the cuff with 10-0 nylon (Fig. 3c) and discard the donor right lung.
28| Place the donor lung on top of retraction clip holding the recipient left lung and cover with small moist gauze. m CRITICAL STEP The recipient left lung is left in place to put tension on the recipient hilum thereby facilitating the anastomosis.
29| Expose the cuffed hilar structures anteriorly and begin the anastomoses by inserting the donor into the recipient PA.
The donor PA will be on some stretch at this point (Fig. 7h) .
30| After donor PA is inserted into the recipient PA, place microclip across the extension of the cuff to keep structures stabilized while securing the previously placed 10-0 nylon tie around the recipient PA and cuff (two knots) (Figs. 3d and 7i) . Remove the microclip from the extension cuff (Fig. 7j) .
? TROUBLESHOOTING 31| Insert the donor bronchus into the recipient bronchus. The donor bronchus is on some stretch (Fig. 7k) .
32| After the donor bronchus is inserted into the recipient bronchus, place the microclip across the extension of cuff to keep structures stabilized while securing the previously placed nylon tie around the recipient bronchus and cuff with two throws (Figs. 3d and 7l) . Remove the microclip from the extension of the bronchial cuff. 33| Insert the donor PV into the recipient PV, with the donor PV slightly stretched (Fig. 7m) . ? TROUBLESHOOTING 34| After the donor PV is inserted into the recipient PV, place the microclip across the extension of the cuff to keep structures stabilized while securing nylon tie around the recipient PV and cuff with two throws (Figs. 3d and 7n ).
35| Release slipknot on the PV first followed by the PA to restore blood flow.
36| Next release the microclip on the bronchus to restore ventilation.
37|
Place the donor lung into the chest cavity and remove the recipient left lung by cutting the remaining pieces of the recipient PA, PV and bronchus posteriorly (Fig. 7o) . Discard the recipient left lung.
38|
Close the chest with 6-0 PDS suture catching one rib above and one rib below the thoracotomy incision. Immediately before closure of the chest, give the animal one large breath to evacuate any remaining air from the chest. Unlike in the rat model, we do not put chest tubes into mice. Close the skin and subcutaneous tissue with a running subcuticular 6-0 PDS suture. ? TROUBLESHOOTING Animal recovery TIMING 12 h 39| Allow the animal to recover with free access to food and water in the small animal ICU overnight.
TIMING
Step 1, preparation of bronchial and vascular cuffs: 10 min for preparation of three cuffs Steps 2-15, donor operation: 10-15 min Steps 16-38, recipient operation: 50-60 min
Step 39, animal recovery: 12 h ? TROUBLESHOOTING Troubleshooting advice can be found in Table 1 . 
